ASX Announcement

Medibio Limited – 17 April 2019



Medibio Announces Sponsored Research Agreement with Humanitas University

Melbourne, Australia and Minneapolis, MN – 17 April 2019: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), a mental health technology company today announces a Sponsored Research Agreement with the Department of Biomedical Sciences of Humanitas University, Milan, Italy.

This research agreement will support the Company's continued development of mental health software products based on Medibio's intellectual property. The collaboration extends the Company's clinical team and will reinforce clinical relevance needed to align with regulatory guidance and market needs. Medibio will maintain all intellectual property generated under this agreement.


Throughout 2019 Medibio will work closely with this highly skilled team of researchers and data-scientists who have clinical backgrounds in Psychiatry and Psychology. The team's depth of expertise is impressive, including collectively publishing 177 peer-reviewed articles focusing on subjects like panic attacks, anxiety disorders and general Psychiatry.

"Technology is the future of medicine and this partnership aligns with our focus on continuous innovation," said Giorgio Ferrari, the CEO of Humanitas University. "Transitioning to a modern culture of research, one which expands beyond the university in collaboration with innovative companies like Medibio, is a priority for us. This is an opportunity to improve the precision in diagnostic assessment and therapeutic choices in the field of mental health."

Overseeing this collaboration will be Dr. Giampaolo Perna, Medibio Scientific Advisory Board member. Giampaolo Perna, M.D., Ph.D. is currently Chair of the Department of Clinical Neurosciences at San Benedetto Menni Hospital of the Hermanas Hospitalarias (Como Lake) and Academic Coordinator of Mental Health Area and Adjunct Professor at Humanitas University (Milan), in Italy. He earned his degree in Medicine and Surgery at the State University of Milan, followed by a Ph.D. and completed a residency in Psychiatry there as well. He is the Chair of WPA section on personalised psychiatry and Coeditor in chief of the Elsevier Journal "Personalized Medicine in Psychiatry".

"Medibio has found an effective partner to assist in developing and validating our pipeline of software products," said Lindsey Hagan, Medibio Vice President, Strategy and Business Development. "The ultimate goal of this collaboration is to release clinical products that are meaningful to both physicians and patients while improving outcomes in mental health care delivery."

ASX Announcement





About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers comprehensive mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

About Humanitas University

Humanitas University is an International Medical School based in Milan, closely integrated with the renowned Humanitas Research and Teaching Hospital. The visiting faculty includes Nobel Prizes in Medicine and internationally renowned researchers. The Scientific Coordinator is Prof. Alberto Mantovani, HUNIMED's Prorector for research. An International Advisory Board, headed by the Nobel Prize awardee Rolf Zinkernagel, assesses and evaluates Humanitas research. In 2017, the scientific production of Humanitas consisted in 776 publications (including 420 ranked in the first decile and the first quartile in their categories as ordered by JCR indicators) with 4.061 of total IF. In addition to the International Medicine course, there is also a degree course in Nursing and one in Physiotherapy. Lessons are held in the new Campus, designed according to the most modern standards in terms of technology and environmental comfort. The aim is to promote exchange opportunities for teachers, researchers and young students from all over the world. In the Campus there is also the Mario Luzzatto Simulation Center and an Anatomy Lab: a 2,000 square meters state-of-the-art Simulation Lab which complements the academic teaching and learning activities to train healthcare professionals.

Further Information:	Website: www.medibio.com.au
Medibio Media Enquiries:	Australian Investor Enquiries:
Kristi Hamilton	Peter Taylor
Director, Strategic Communications	NWR Communications
Medibio Limited	peter@nwrcommunications.com.au
kristi.hamilton@medibio.com.au	T: +61 (0) 412 036 231
T: +1 952 232 0934	